|
|
|
|
|
SYDNEY, AU, June 23, 2017 - (ACN Newswire) - Asia Pacific specialist CRO Novotech announced today it has expanded its business offering to include central lab services through a preferred partnership agreement with Sonic Clinical Trials, an affiliate of international healthcare company, Sonic Healthcare.
Through this unique partnership, Novotech clients will be able to select from a wide menu of assays or biomarkers, access a trial-specific kit assembly service and use a single clinical trial-dedicated laboratory with a global reach, for priority processing of clinical trial samples.
Announcing the new partnership, Novotech CEO Dr. John Moller said, "Novotech has always focused on offering flexible and cost effective clinical trial solutions. Through our partnership with Sonic Clinical Trials, our clients will experience a seamless integration of laboratory services and clinical trial data management by Novotech. From the start to finish, our clients are supported by a team of dedicated project managers.
"Another key benefit to our clients is the fact that Sonic Clinical Trials is pre-audited and an approved Novotech vendor. This removes our clients' need to undertake their own central lab vendor assurance - providing a further savings in cost and clinical trial time."
Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry, a division of the Australian Government's Department of Industry, Innovation and Science.
"Sonic Clinical Trials' RSP status assists our eligible international clients when accessing the Australian R&D Tax Incentive Scheme. Research from a recent Frost and Sullivan white paper revealed that eligible companies can conduct early stage clinical trials 60% more cheaply in Australia than the USA," explained Dr. Moller.
"Novotech's size and Asia Pacific focus allows our clients to enjoy a direct, hands-on approach to accessing some of the largest patient pools in the world, but we balance this with providing global gold-standard central laboratory services and data management platforms."
About Australian R&D Tax Incentive Scheme
Through the Australian R&D Tax Incentive Scheme, eligible companies may claim a 43.5% R&D tax refund on eligible R&D expenditure. For more information about this scheme, see the joint Novotech / Frost & Sullivan white paper, "Australia: The preferred destination for early phase clinical trials", Mar. 31, 2017. http://novotech-cro.com/news-events.
About Sonic Clinical Trials
Sonic Clinical Trials is a wholly owned subsidiary of Australian-owned Sonic Healthcare, one of the world's largest specialist medical diagnostics companies, employing more than 33,000 people in Australia, New Zealand, the United Kingdom, Germany, Switzerland, Belgium, Ireland and the USA. Sonic Clinical Trials is a registered Research Service Provider (RSP) with AusIndustry which allows it to assist international clients to register for the Australian R&D Tax Incentive Scheme. To learn more, please visit www.sonicclinicaltrials.com.au.
About Novotech
Headquartered in Sydney, Novotech is internationally recognised as the leading regional full-service contract research organisation (CRO). With a focus on clinical monitoring, Novotech has been instrumental in the success of hundreds of Phase I - IV clinical trials in the Asia Pacific region, while it has worldwide reach through its network of strategic partners.
Novotech provides clinical development services across all clinical trial phases and therapeutic areas including: feasibility assessments; ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, report write-up to ICH requirements, project and vendor management. For more information, please visit www.novotech-cro.com.
Media:
Digital Mantra Group
Susan Fitzpatrick-Napier
AU: +61 2 8218 2144 / USA: +1 650 798 5238
Email: susan@dmgpr.com
Corporate:
Novotech
Justine Lamond
Marketing & Communications Manager
AU: +61 2 8569 1458
Email: communications@novotech-cro.com
Topic: Clinical Trial Results
Source: Novotech Health Holdings Pte Ltd
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Novotech Health Holdings Pte Ltd |
| Feb 15, 2023 09:00 HKT/SGT |
|
The Evolving Global Landscape in Vaccine Development: Novotech and Endpoints News Webinar |
| Feb 10, 2023 19:00 HKT/SGT |
|
Novotech Global Report: Robust Phase 1 Trial Growth Across Asia Pacific |
| Feb 3, 2023 13:00 HKT/SGT |
|
Asia Pacific Cell & Gene Research Growing 50% Faster than ROW |
| Jan 12, 2023 15:00 HKT/SGT |
|
Novotech Acquires European CRO, Strengthens Global Operations |
| Jan 12, 2023 15:00 HKT/SGT |
|
Novotech Acquires US-based Drug Development Consulting Firm, CBR International |
| Dec 20, 2022 11:00 HKT/SGT |
|
Novotech is Gold Sponsor at Biotech Showcase 2023 |
| Dec 15, 2022 10:00 HKT/SGT |
|
Data Shows 50% of New Trials Have Sites in Asia Pacific |
| Dec 6, 2022 11:00 HKT/SGT |
|
Novotech Awarded the Asia Pacific CRO of the Year 2022 for Best Practices in Clinical Trials |
| Nov 11, 2022 17:00 HKT/SGT |
|
Novotech Chairs BioCentury Summit Workshop on How to Build and Finance an East-West MRCT Strategy |
| Oct 25, 2022 18:00 HKT/SGT |
|
Clinical Research Opportunities in China and the Path to USFDA Approval - Whitepaper |
| More news >> |
 |
|
|
|
